A urinary DNA methylation test demonstrated a high sensitivity for detecting high-grade or invasive bladder cancer, ...

The following is a summary of “Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stage IV ovarian cancer: a nationwide population ...

Outpatient management of patients with cancer-associated pulmonary embolism (PE) may be a feasible, safe approach with low short-term rates of recurrent venous thromboembolism (VTE), major bleeding, ...

Leaders of the Common Sense Oncology initiative, launched 1.5 years ago as “a new patient-centered movement in cancer care,” outline principles for trial design, analysis, and reporting.

A Personal View published in The Lancet Oncology challenges the long-standing perception of metastatic brain cancer, calling ...

Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its ...

About Veru Inc. Veru is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic diseases, oncology, and ARDS. The Company’s drug ...

The management of bone metastases in endocrine-related cancers is a continually evolving field, marked by significant challenges and advances that affect ...

Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive ...

Lung metastases are a devastating reality for over half of cancer patients whose tumors spread beyond their initial sites.

Patients with appendiceal adenocarcinoma have a 7.5% risk of second primary cancer within 10 years. There is a 12% excess incidence of secondary primary cancers, particularly colorectal, in these ...

Patients with appendiceal adenocarcinoma face increased risk of secondary cancers, including colorectal, within 10 years, per 2025 ASCO GI findings. In adults diagnosed with a first primary ...